1.24
전일 마감가:
$1.17
열려 있는:
$1.18
하루 거래량:
1.36M
Relative Volume:
1.15
시가총액:
$57.19M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-0.747
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
-21.02%
1개월 성능:
-31.30%
6개월 성능:
-73.10%
1년 성능:
-92.48%
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CABA
Cabaletta Bio Inc
|
1.24 | 57.19M | 0 | -67.68M | -54.24M | -1.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2024-10-10 | 개시 | UBS | Buy |
2024-02-05 | 개시 | Jefferies | Buy |
2023-11-29 | 개시 | William Blair | Outperform |
2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
2023-10-19 | 개시 | Stifel | Buy |
2023-09-05 | 개시 | Citigroup | Buy |
2023-07-18 | 개시 | Guggenheim | Buy |
2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-12-08 | 개시 | Wells Fargo | Overweight |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-06-30 | 개시 | Mizuho | Buy |
2021-01-08 | 개시 | Chardan Capital Markets | Buy |
2020-10-13 | 개시 | H.C. Wainwright | Buy |
2019-11-19 | 개시 | Cowen | Outperform |
2019-11-19 | 개시 | Evercore ISI | Outperform |
2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat
Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN
Cabaletta Bio (NASDAQ:CABA) Price Target Lowered to $7.00 at UBS Group - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com
Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com
UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener
Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks
Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada
Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India
BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cabaletta Bio, Inc. SEC 10-K Report - TradingView
Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan
Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia
Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire
Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com Australia
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - TradingView
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):